Literature DB >> 33371215

Virus-Like Particle Mediated CRISPR/Cas9 Delivery for Efficient and Safe Genome Editing.

Pin Lyu1, Luxi Wang2, Baisong Lu3.   

Abstract

The discovery of designer nucleases has made genome editing much more efficient than before. The designer nucleases have been widely used for mechanistic studies, animal model generation and gene therapy development. However, potential off-targets and host immune responses are issues still need to be addressed for in vivo uses, especially clinical applications. Short term expression of the designer nucleases is necessary to reduce both risks. Currently, various delivery methods are being developed for transient expression of designer nucleases including Zinc Finger Nuclease (ZNF), Transcription Activator-Like Effector Nuclease (TALEN) and Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated (CRISPR/Cas). Recently, virus-like particles are being used for gene editing. In this review, we will talk through commonly used genome editing nucleases, discuss gene editing delivery tools and review the latest literature using virus-like particles to deliver gene editing effectors.

Entities:  

Keywords:  CRISPR/Cas9; RNA; TALEN; ZFN; delivery; designer nuclease; gene editing; ribonucleoprotein; viral capsid; virus-like particle (VLP)

Year:  2020        PMID: 33371215      PMCID: PMC7766694          DOI: 10.3390/life10120366

Source DB:  PubMed          Journal:  Life (Basel)        ISSN: 2075-1729


  111 in total

1.  Virus shapes and buckling transitions in spherical shells.

Authors:  Jack Lidmar; Leonid Mirny; David R Nelson
Journal:  Phys Rev E Stat Nonlin Soft Matter Phys       Date:  2003-11-25

2.  Deregulation of microRNAs by HIV-1 Vpr protein leads to the development of neurocognitive disorders.

Authors:  Ruma Mukerjee; J Robert Chang; Luis Del Valle; Asen Bagashev; Monika M Gayed; Randolph B Lyde; Brian J Hawkins; Eugen Brailoiu; Eric Cohen; Chris Power; S Ausim Azizi; Benjamin B Gelman; Bassel E Sawaya
Journal:  J Biol Chem       Date:  2011-08-04       Impact factor: 5.157

3.  Bacterial Genome Editing with CRISPR-Cas9: Taking Clostridium beijerinckii as an Example.

Authors:  Zhong-Tian Zhang; Pablo Jiménez-Bonilla; Seung-Oh Seo; Ting Lu; Yong-Su Jin; Hans P Blaschek; Yi Wang
Journal:  Methods Mol Biol       Date:  2018

4.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

5.  Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases.

Authors:  Ulrike Mock; Kristoffer Riecken; Belinda Berdien; Waseem Qasim; Emma Chan; Toni Cathomen; Boris Fehse
Journal:  Sci Rep       Date:  2014-09-18       Impact factor: 4.379

6.  The cooperative function of arginine residues in the Prototype Foamy Virus Gag C-terminus mediates viral and cellular RNA encapsidation.

Authors:  Martin V Hamann; Erik Müllers; Juliane Reh; Nicole Stanke; Gregory Effantin; Winfried Weissenhorn; Dirk Lindemann
Journal:  Retrovirology       Date:  2014-10-08       Impact factor: 4.602

7.  Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout.

Authors:  Yvonne Knopp; Franziska K Geis; Dirk Heckl; Stefan Horn; Thomas Neumann; Johannes Kuehle; Janine Meyer; Boris Fehse; Christopher Baum; Michael Morgan; Johann Meyer; Axel Schambach; Melanie Galla
Journal:  Mol Ther Nucleic Acids       Date:  2018-09-13       Impact factor: 8.886

8.  Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Yaoying Wu; Matthew P Gemberling; Matthew L Oliver; Matthew A Waller; Joel D Bohning; Jacqueline N Robinson-Hamm; Karen Bulaklak; Ruth M Castellanos Rivera; Joel H Collier; Aravind Asokan; Charles A Gersbach
Journal:  Nat Med       Date:  2019-02-18       Impact factor: 53.440

9.  CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity.

Authors:  Thomas J Cradick; Eli J Fine; Christopher J Antico; Gang Bao
Journal:  Nucleic Acids Res       Date:  2013-08-11       Impact factor: 16.971

10.  Nucleosome breathing and remodeling constrain CRISPR-Cas9 function.

Authors:  R Stefan Isaac; Fuguo Jiang; Jennifer A Doudna; Wendell A Lim; Geeta J Narlikar; Ricardo Almeida
Journal:  Elife       Date:  2016-04-28       Impact factor: 8.140

View more
  10 in total

Review 1.  Therapeutic in vivo delivery of gene editing agents.

Authors:  Aditya Raguram; Samagya Banskota; David R Liu
Journal:  Cell       Date:  2022-07-06       Impact factor: 66.850

Review 2.  Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.

Authors:  Chiara Rinoldi; Seyed Shahrooz Zargarian; Pawel Nakielski; Xiaoran Li; Anna Liguori; Francesca Petronella; Dario Presutti; Qiusheng Wang; Marco Costantini; Luciano De Sio; Chiara Gualandi; Bin Ding; Filippo Pierini
Journal:  Small Methods       Date:  2021-07-28

Review 3.  CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.

Authors:  Hanan Bloomer; Jennifer Khirallah; Yamin Li; Qiaobing Xu
Journal:  Adv Drug Deliv Rev       Date:  2021-12-20       Impact factor: 15.470

Review 4.  In vivo somatic cell base editing and prime editing.

Authors:  Gregory A Newby; David R Liu
Journal:  Mol Ther       Date:  2021-09-10       Impact factor: 11.454

5.  Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing.

Authors:  Xingang Yao; Pin Lyu; Kyung Yoo; Manish Kumar Yadav; Ravi Singh; Anthony Atala; Baisong Lu
Journal:  J Extracell Vesicles       Date:  2021-03-16

6.  Improved alpharetrovirus-based Gag.MS2 particles for efficient and transient delivery of CRISPR-Cas9 into target cells.

Authors:  Yvonne Baron; Johanna Sens; Lucas Lange; Larissa Nassauer; Denise Klatt; Dirk Hoffmann; Marc-Jens Kleppa; Philippe Vollmer Barbosa; Maximilian Keisker; Viviane Steinberg; Julia D Suerth; Florian W R Vondran; Johann Meyer; Michael Morgan; Axel Schambach; Melanie Galla
Journal:  Mol Ther Nucleic Acids       Date:  2022-01-01       Impact factor: 8.886

Review 7.  New Advances in Using Virus-like Particles and Related Technologies for Eukaryotic Genome Editing Delivery.

Authors:  Pin Lyu; Baisong Lu
Journal:  Int J Mol Sci       Date:  2022-08-06       Impact factor: 6.208

Review 8.  Recent Advances in Improving Gene-Editing Specificity through CRISPR-Cas9 Nuclease Engineering.

Authors:  Xiaoqiang Huang; Dongshan Yang; Jifeng Zhang; Jie Xu; Y Eugene Chen
Journal:  Cells       Date:  2022-07-13       Impact factor: 7.666

Review 9.  The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy.

Authors:  Ning Guo; Ji-Bin Liu; Wen Li; Yu-Shui Ma; Da Fu
Journal:  J Adv Res       Date:  2021-12-04       Impact factor: 12.822

Review 10.  CRISPR based therapeutics: a new paradigm in cancer precision medicine.

Authors:  Shehnaz Bano; Prachi Kapse; Sumit Das; Gopal C Kundu
Journal:  Mol Cancer       Date:  2022-03-25       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.